Drug Profile


Alternative Names: HAP 302; TH-302; TH302-cpd

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Threshold Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Developer Grupo Espanol de Tumores Neuroendocrinos; Merck KGaA; Molecular Templates; Threshold Pharmaceuticals; University of Texas Health Science Center at San Antonio; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Nitroimidazoles; Phosphoramide mustards; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Biliary cancer; Glioblastoma
  • Phase I Solid tumours
  • Suspended Leukaemia; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer
  • Discontinued Soft tissue sarcoma

Most Recent Events

  • 02 Aug 2017 Molecular Templates merged with Threshold Pharmaceuticals and the later company changed its name to Molecular Templates
  • 10 May 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03098160)
  • 27 Mar 2017 Evofosfamide is still at phase III development stage for Pancreatic cancer in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top